Engineered virus halts pancreatic cancer in three patients, University of Minnesota reports
Pancreatic cancer halted by virus injection in three patients

In a Phase I trial at the University of Minnesota, three people with inoperable pancreatic cancer received RGDCRAdCOX2F, a genetically modified adenovirus injected directly into tumors. All three survived beyond six months, and one has had disease control for 15 months. The trial's primary goal is safety and dosing, not efficacy, and researchers caution that three cases cannot establish a success rate or prove survival benefit.
The scientific interest is substantial: a biological agent that can multiply inside its target offers a different way to attack a difficult cancer.